HealthPembrolizumab-Olaparib Delays Progression in Ovarian Cancer
Phase 3 clinical trial results indicate that the combination of pembrolizumab and olaparib significantly prolonged progression-free survival in patients with advanced ovarian cancer without BRCA mutations. This finding suggests a new effective treatment option for this patient group, potentially improving outcomes in a challenging cancer subtype.
European Medical Journal·



